TB-500 vs AHK (Ala-His-Lys)

TB-500 and AHK (Ala-His-Lys) represent two distinct classes of peptides studied for regenerative research. TB-500, derived from thymosin beta-4, is a well-characterized synthetic fragment with a growing body of clinical evidence, including randomized controlled trials for wound healing and dry eye. In contrast, AHK is a copper-binding tripeptide related to GHK, with research limited to in vitro and animal models. This comparison highlights their divergent mechanisms, evidence bases, and experimental applications to inform research design.

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4) containing the active healing sequence Ac-LKKTETQ (molecular weight ~889 g/mol). Its primary mechanism involves promoting cell migration, angiogenesis, and tissue repair by binding to actin and modulating cytoskeletal dynamics. Evidence includes several human randomized controlled trials for wound healing and dry eye, as well as a dedicated safety trial in 40 healthy adults that reported minimal adverse effects. Despite this, TB-500 remains unapproved for therapeutic use in major markets and is prohibited by WADA and horse racing authorities. Key research claims include accelerated wound healing, reduced inflammation, and cardiac repair in preclinical models.

AHK (alanyl-histidyl-lysine) is a tripeptide structurally related to GHK (glycyl-histidyl-lysine) and shares its copper-binding properties. It is hypothesized to stimulate hair follicle growth and promote wound healing through collagen synthesis and growth factor upregulation, likely via copper-dependent signaling pathways. However, evidence is limited to in vitro studies and animal models, with no human clinical trials published to date. Key research claims include stimulating hair growth and promoting wound healing, but these are based on preliminary data and require further validation.

TB-500 and AHK target distinct research areas with minimal overlap. TB-500 is primarily studied in injury recovery and anti-inflammatory contexts, including wound healing, cardiac repair, and musculoskeletal regeneration. AHK focuses on hair growth and skin health, with applications in dermatological research. Researchers should consider these divergent focuses when designing studies, as the peptides are not interchangeable and address different biological processes.

TB-500 has the most robust safety data among the two, including a dedicated safety trial in 40 healthy adults (2010) that found minimal adverse effects. Common anecdotal side effects include injection site pain, lightheadedness, mild headache, nausea, and fatigue, but no significant safety concerns have been reported in published human studies. In contrast, AHK has minimal safety data available, as it remains a research-only compound with no human trials. Researchers should exercise caution with AHK and adhere to appropriate laboratory safety protocols.